FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL										
l	OMB Number:	3235-0287									
l	Estimated average burden										
I	hours per response:	0.5									

	Check this box if no longer subject to									
١	Section 16. Form 4 or Form 5									
J	obligations may continue. See									
	Instruction 1(b)									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Moseley Ken						2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC [BLCM]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify				
(Last) (First) (Middle) C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800						3. Date of Earliest Transaction (Month/Day/Year) 07/03/2017								Sr. V	VP and Ge	below neral Counse	1	
(Street) HOUSTON TX 77030			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)																		
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					action Day/Yea	2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transacti Code (Ins 8)	on Dis str. 5)	Securit sposed nount	ies Acquire Of (D) (Inst	d (A) or tr. 3, 4 and Price	5. Amou Securitie Beneficia Owned F Reported Transact (Instr. 3 a	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		7	Table II - D)						uired, Dis , options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate, T	ransac Code (li				6. Date Exercisable and Expiration Date (Month/Day/Year)		and	7. Title and Amor of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisable	Expira Date	ation	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$11.7	07/03/2017			A		26,250		(1)	07/02/	/2027	Common Stock	26,250	\$0	26,250	D		
Stock Option (right to buy)	\$11.7	07/03/2017			A		42,000		(1)	07/02/	/2027	Common Stock	42,000	\$0	42,000	I	Annemarie Moseley, Ph.D., M.D. ⁽²⁾	

Explanation of Responses:

- 1. 25% of the shares subject to the stock option vest and become exercisable on January 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 2. The Reporting Person's spouse is Annemarie Moseley, Consultant to Bellicum, formerly COO/EVP Clinical Development. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

/s/ Ken Moseley J.D.

07/06/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.